

Alaa Alotaibi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5235403/alaa-alotaibi-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers

7,370
citations

35
h-index

85
g-index

131
ext. papers

9,565
ext. citations

7
avg, IF

5.79
L-index

#	Paper	IF	Citations
124	Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis.. <i>Clinical Neurophysiology</i> , 2022 , 136, 69-81	4.3	
123	High or increasing serum NFL is predictive of impending multiple sclerosis relapses.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 59, 103535	4	3
122	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061861	5	1
121	Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 61, 103779	4	0
120	Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol.. <i>Current Protocols</i> , 2022 , 2, e437		
119	Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 167-173	5	1
118	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. <i>Lancet Neurology</i> , 2021 , 20, 917-929 ^{24.1}		9
117	Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. <i>CNS Drugs</i> , 2021 , 35, 385-402	6.7	11
116	MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 49, 102790	4	1
115	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2021 , 78, 558-567	17.2	39
114	Physical Activity Together for People With Multiple Sclerosis and Their Care Partners: Protocol for a Feasibility Randomized Controlled Trial of a Dyadic Intervention. <i>JMIR Research Protocols</i> , 2021 , 10, e184 ²¹⁰		0
113	Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021 , 421, 117324	3.2	0
112	Serum neurofilament light in MS: The first true blood-based biomarker?. <i>Multiple Sclerosis Journal</i> , 2021 , 1352458521993066	5	11
111	Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation. <i>Frontiers in Neuroscience</i> , 2021 , 15, 654942	5.1	11
110	A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 52, 102945	4	4
109	Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study. <i>CNS Drugs</i> , 2021 , 35, 1009-1022	6.7	0
108	Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211035740	5	2

107	Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 56, 103283	4	1
106	Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION. <i>Journal of Neuroimmunology</i> , 2021 , 360, 577715	3.5	0
105	Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 2055217321990852	2	1
104	Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2020 , 47, 437-455	1	18
103	COVID-19 in teriflunomide-treated patients with multiple sclerosis. <i>Journal of Neurology</i> , 2020 , 267, 2796-279637	9.3	37
102	Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. <i>Scientific Reports</i> , 2020 , 10, 10381	4.9	35
101	Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 540-547	5	13
100	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. <i>CNS Drugs</i> , 2020 , 34, 185-196	6.7	32
99	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020 , 6, 2055217320972137	2	2
98	Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1729-1739	5	22
97	Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1719-1728	5	8
96	Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis. <i>BMC Neurology</i> , 2020 , 20, 364	3.1	1
95	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2020 , 19, 988-997	24.1	28
94	Blood Neurofilament Light Chain: The Neurologist's Troponin?. <i>Biomedicines</i> , 2020 , 8,	4.8	18
93	Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102438	4	7
92	Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1083-1092	5	15
91	Does Resetting the Immune System Fix Multiple Sclerosis?. <i>Canadian Journal of Neurological Sciences</i> , 2020 , 47, 1-10	1	4
90	Clinical and MRI efficacy of sc IFN β 1a in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. <i>Journal of Neurology</i> , 2020 , 267, 64-75	5.5	1

89	Imaging cognitive fatigability in multiple sclerosis: objective quantification of cerebral blood flow during a task of sustained attention using ASL perfusion fMRI. <i>Brain Imaging and Behavior</i> , 2020 , 14, 2417-2428 ⁹	4.1	2428 ⁹
88	Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 767-775	5.3	10
87	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 33, 131-138	4	12
86	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. <i>Trials</i> , 2019 , 20, 263	2.8	41
85	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 845-854	4.7	46
84	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β 1a. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101891	4	1
83	Effect of different doses of gadolinium contrast agent on clinical outcomes in MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217318823796	2	6
82	High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e598	9.1	26
81	Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319885983	2	12
80	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. <i>Brain Imaging and Behavior</i> , 2019 , 13, 1361-1374	4.1	14
79	gMS-Classifer1 does not predict disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1010-1011	5	
78	Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. <i>Journal of Clinical Neuroscience</i> , 2019 , 59, 229-231	2.2	1
77	Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1764-1772	5	9
76	Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	13
75	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 565-573	5	4
74	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , 2018 , 17, 162-173	24.1	2419
73	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 346-356	5.3	13
72	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , 2018 , 17, 405-415	24.1	150

71	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 535-539	5	11
70	Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1055-1066	5	6
69	Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2018 , 9, 834	8.4	28
68	Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. <i>Canadian Journal of Neurological Sciences</i> , 2018 , 45, 489-503	1	25
67	Predictors of response to opicinumab in acute optic neuritis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1154-1162	5.3	15
66	Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318775236	2	1
65	Disability progression in aggressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 456-463	5	11
64	Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 420-431	5	22
63	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 94-105	5	56
62	Subcutaneous interferon β 1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 285-294	5.5	23
61	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , 2017 , 74, 459-469	17.2	147
60	Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. <i>Journal of Neurology</i> , 2017 , 264, 1068-1075	5.5	18
59	Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 2122-2133	59.2	111
58	Immunoablation and aHSCT for aggressive multiple sclerosis - AuthorsReply. <i>Lancet, The</i> , 2017 , 389, 908	40	1
57	A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017 , 3, 2055217317730096	2	15
56	The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017 , 3, 2055217317732802	2	17
55	Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017 , 14, 888-893	6.4	12
54	Early MRI results and odds of attaining Qo evidence of disease activity status in MS patients treated with interferon β 1a in the EVIDENCE study. <i>Journal of the Neurological Sciences</i> , 2017 , 379, 151-156	3.2	8

53	Efficacy and safety of teriflunomide in chinese patients with relapsing forms of ms: a subgroup analysis of the phase 3 tower study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, e1.22-e1.5	5.5	1.5
52	PO152 Alemtuzumab efficacy in patients with relapse after course 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A53.1-A53	5.5	
51	The evaluation of MRI diffusion values of active demyelinating lesions in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 97-102	4	10
50	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. <i>Lancet, The</i> , 2016 , 388, 576-85	40	234
49	Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 7, 33-40	4	17
48	Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. <i>Therapeutic Advances in Chronic Disease</i> , 2016 , 7, 18-33	4.9	57
47	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016 , 387, 1075-1084	40	271
46	Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Canadian contribution to the international validation project. <i>Journal of the Neurological Sciences</i> , 2016 , 362, 147-52	3.2	44
45	Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. <i>Neurology</i> , 2016 , 86, 920-30	6.5	80
44	Inclusion of brain volume loss in a revised measure of Qo evidence of disease activity (NEDA-4) in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1297-305	5	169
43	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. <i>JAMA Neurology</i> , 2016 , 73, 1089-98	17.2	67
42	Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 204-212	4	28
41	Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 5, 97-104	4	59
40	Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring. <i>Canadian Journal of Neurological Sciences</i> , 2016 , 43, 278-83	1	16
39	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016 , 87, 978-87	7.5	78
38	Evaluating response to disease-modifying therapy in relapsing multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 407-23	4.3	4
37	Neuro-oncology dilemma: Tumour or tumefactive demyelinating lesion. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 555-66	4	24
36	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , 2015 , 85, 1694-701	6.5	39

35	Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management. <i>Canadian Journal of Neurological Sciences</i> , 2015 , 42, 284-91	1	14
34	Aggressive multiple sclerosis: proposed definition and treatment algorithm. <i>Nature Reviews Neurology</i> , 2015 , 11, 379-89	15	82
33	Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , 2014 , 13, 247-56	24.1	363
32	Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization. <i>Journal of the Neurological Sciences</i> , 2014 , 339, 196-206	3.2	21
31	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. <i>Annals of Clinical and Translational Neurology</i> , 2014 , 1, 605-17	5.3	39
30	First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient Outcomes (EPOC) study in relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 620-8	4	12
29	Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 696-704	4	76
28	Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , 2014 , 13, 977-86	24.1	208
27	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology, The</i> , 2014 , 13, 257-67	24.1	156
26	Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. <i>Therapeutic Advances in Neurological Disorders</i> , 2014 , 7, 279-88	6.6	9
25	Efficacy and safety of subcutaneous interferon-β1a in patients with a first demyelinating event and early multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1207-14	5.4	4
24	Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1198-208	5.5	105
23	Anti-JC Virus Antibody Prevalence in Canadian MS Patients. <i>Canadian Journal of Neurological Sciences</i> , 2014 , 41, 748-52	1	13
22	Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation. <i>Journal of the Neurological Sciences</i> , 2014 , 336, 132-7	3.2	9
21	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 147-55	4	43
20	Atacept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Neurology, The</i> , 2014 , 13, 353-63	24.1	212
19	Patient subgroup analyses of the treatment effect of subcutaneous interferon β1a on development of multiple sclerosis in the randomized controlled REFLEX study. <i>Journal of Neurology</i> , 2014 , 261, 490-9	5.5	12
18	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. <i>Lancet Neurology, The</i> , 2013 , 12, 756-67	24.1	163

17	Present and emerging therapies for multiple sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013 , 19, 968-91	3	6
16	Teriflunomide in relapsing multiple sclerosis: therapeutic utility. <i>Therapeutic Advances in Chronic Disease</i> , 2013 , 4, 192-205	4.9	22
15	Treatment optimization in MS: Canadian MS Working Group updated recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2013 , 40, 307-23	1	159
14	Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. <i>Journal of Clinical & Cellular Immunology</i> , 2013 , 4,	2.7	28
13	Cognitive impact of anticholinergic medication in MS: Adding insult to injury?. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 156-61	4	12
12	Do not treat from CIS onset: evaluate disease course and prognosis first--no (treat!). <i>Multiple Sclerosis Journal</i> , 2012 , 18, 394-5	5	4
11	Tests of information processing speed: what do people with multiple sclerosis think about them?. <i>International Journal of MS Care</i> , 2012 , 14, 92-9	2.3	16
10	Managing relapsing-remitting multiple sclerosis following first drug failure. <i>Neurodegenerative Disease Management</i> , 2011 , 1, 115-126	2.8	
9	Long-term follow-up of clinical trials of multiple sclerosis therapies. <i>Neurology</i> , 2011 , 76, S26-34	6.5	51
8	Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence. <i>Neurology: Clinical Practice</i> , 2011 , 1, 66-68	1.7	10
7	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 503-10	5	185
6	Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidence. <i>Neurological Sciences</i> , 2008 , 29 Suppl 2, S250-2	3.5	16
5	Bone marrow transplantation: does it stop MS progression?. <i>Journal of the Neurological Sciences</i> , 2007 , 259, 85-9	3.2	16
4	Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. <i>Archives of Neurology</i> , 2005 , 62, 865-70		348
3	Primary progressive multiple sclerosis: cerebrospinal fluid considerations. <i>Multiple Sclerosis Journal</i> , 2004 , 10 Suppl 1, S31-4; discussion S34-5	5	1
2	Treatment optimization in multiple sclerosis. <i>Canadian Journal of Neurological Sciences</i> , 2004 , 31, 157-68		93
1	Immunologic therapy for relapsing-remitting multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2001 , 1, 277-85	6.6	7